Academia sponsored trials with public funding are crucial for survival gains, reveals our policy paper. We reviewed the sponsorship and funding of random­ised controlled trials (RCTs) demonstrating life-extending outcomes in non-small cell lung cancer. While reaffirming the important contribution that industry makes in funding RCTs for developing new drugs to treat advanced disease, our findings also reveal the critical role that academic groups and public funding plays in identifying inter­ventions that yield the biggest public health benefits, highlighting the val­ue of continued public funding and support of academic trials.

Read the full article here